Algernon Pharmaceuticals CEO, Christopher Moreau and CSO, Dr. Mark Williams discuss the interim data report from the Company’s Phase 2b/3 Ifenprodil COVID-19 clinical trial


Algernon Pharmaceuticals CEO, Christopher J. Moreau and CSO, Dr. Mark Williams with guests Dr. Mark Swaim and Steve Palmer joined Cyndi Edwards, host of StreetSmart Live! as they discuss the company receiving positive trending interim data from their Phase 2b/3 clinical study of Ifenprodil for COVID-19.

Learn more about Algernon’s COVID-19 interim data, hear what the final data report will Include and a discussion regarding the importance of COVID-19 therapeutics.